The Cancer Vaccine collaboration with the Institute for Respiratory Health (IRH) to evaluate the in vivo
effectiveness of BARD1 peptide vaccine formulations for triggering immune response and inhibiting tumour
growth in animal models continued during the quarter, with the peptide vaccine results expected in
December 2018.
Taken from the quaterly report. I see vaccine.
- Forums
- ASX - By Stock
- IIQ
- Ann: Ceasing to be a substantial holder
Ann: Ceasing to be a substantial holder, page-161
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
56.0¢ |
Change
0.005(0.90%) |
Mkt cap ! $62.03M |
Open | High | Low | Value | Volume |
56.0¢ | 57.0¢ | 55.5¢ | $20.17K | 35.99K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 20494 | 55.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
57.5¢ | 8700 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 20494 | 0.550 |
1 | 10000 | 0.545 |
3 | 4113 | 0.540 |
1 | 10000 | 0.535 |
3 | 23000 | 0.530 |
Price($) | Vol. | No. |
---|---|---|
0.575 | 8700 | 1 |
0.580 | 1116 | 1 |
0.595 | 5000 | 1 |
0.600 | 46800 | 3 |
0.610 | 15000 | 1 |
Last trade - 15.57pm 03/09/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |